Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06880835 · ClinicalTrials.gov registry record · NA

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

A NA study of Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT06880835: Recruiting NA study of Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research.

NCT06880835 is a NA study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 30 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06880835, a NA study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Jaeb Center for Health Research.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

Primary Outcome

Blood glucose \<70 mg/dL within 90 minutes from the start of exercise

Conditions Studied

Interventions

  • DEVICE Control IQ + sleep activity with TI

Study Locations (3)

Kentucky

  • University of Louisville - Louisville

Pennsylvania

  • University of Pennsylvania - Philadelphia

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-06-05
Est. Completion 2026-05-31
Phase NA
Jaeb Center for Health Research

119 total trials

What NCT06880835 shows while recruiting

NCT06880835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Control IQ + sleep activity with TI is the first listed.

NCT06880835 reports a single indexed study location in Kentucky, Pennsylvania, Washington.

Frequently Asked Questions

What is clinical trial NCT06880835 about?

NCT06880835 is a clinical study titled "Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery". This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). Th...

What is the current status of trial NCT06880835?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-05. Estimated completion is 2026-05-31.

What conditions does trial NCT06880835 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT06880835?

The interventions under investigation include: Control IQ + sleep activity with TI (DEVICE).

Who is sponsoring clinical trial NCT06880835?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06880835 being conducted?

This trial has 3 study locations across Kentucky, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06880835's enrollment target sits among peer trials

30 89th of 118 higher than 30 of 118 other Diabetes Mellitus, Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06880835, the US trial registry maintained by the National Library of Medicine. NCT06880835 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.